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1. INTRODUCTION 
The formation of the connective tissue matrix 
requires the ordered interaction of multiple 
macromolecular components, most notably the 
fibrillar and non-fibrillar collagens, elastin, pro- 
teoglycans, glycosaminoglycans, and glycoproteins 
like fibronectin or laminin [1]. As each of these 
cellular products displays specific binding sites for 
association with identical or non-identical matrix 
molecules, or with an arrangement already formed 
by them, the interaction of these components oc- 
curs as a self-organizing process, as exemplified by 
the auto-generation of highly ordered collagen 
fibrils from type I collagen molecules [2]. 
This self-organizing process can be controlled 
most efficiently by regulating the availability of the 
individual components. Procollagen peptides, for 
example, have been reported to suppress collagen 
biosynthesis at both the pre-translational and 
translational levels [3] and to inhibit fibronectin 
biosynthesis post-transcriptionally [4]. In addition 
Correspondence address: H.M. Hanauske-Abel, 
Laboratory of Human Biochemistry, Enders Pediatric 
Research Building, The Children's Hospital Medical 
Center, Harvard Medical School, 300 Longwood 
Avenue, Boston, MA 02115, USA 
tO such feed-back mechanisms that govern matrix 
formation via the production of individual com- 
ponents, experimental evidence also suggests that 
the processing of the individual components' 
precursors may be modulated to alter the structure 
and function of connective tissue: while matrix ac- 
cumulation of elastin is strikingly reduced by in- 
creasing its hydroxyproline content [5-7], that of 
fibrillar collagen is strikingly reduced by decreas- 
ing it [8]. Obviously, hydroxyproline has an- 
tagonistic functions in these major matrix 
components. In elastin, it interferes with fiber for- 
mation, i.e. coacervation, at 37°C [9] and subse- 
quent cross-link synthesis [5]; in collagen, it is 
indispensible for fiber formation - the stability of 
the individual molecule's triple helix as well as the 
secretion of collagen at 37°C [8] depend on prolyl 
hydroxylation. 
In these two classes of structural proteins which 
simultaneously can be synthesized by the same cell 
population [10,11], each processing event - pep- 
tidyl hydroxyproline formation and cross-link- 
stabilized matrix accumulation - is catalyzed by a 
specific enzyme, the intracellularly active prolyl 
4-hydroxylase [12] and the extracellularly active 
lysyl oxidase [13], respectively. Both enzymes 
utilize unmodified elastin and unmodified collagen 
[12-15]; experimental evidence for peptide 
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substrate-specific isoenzymes is not available. 
Thus, the opposing effect of hydroxyprolyl in 
elastin and in collagen on their matrix accumula- 
tion necessitates a modulating mechanism that 
directs the two enzymes' activity towards a dif- 
ferential processing of each of these essential con- 
nective tissue components, a processing that is 
prerequisite o their physiologically useful deposi- 
tion. Any modulation of their hydroxyproline con- 
tent must result in the formation of a highly 
inhomogeneous, yet ordered pericellular matrix; 
vice versa, the morphologically complex connec- 
tive tissue synthesized by certain cells, e.g. smooth 
muscle cells [1], could in part reflect the time 
course of the differential activity of prolyl 
4-hydroxylase and lysyl oxidase. Molecules able to 
modulate both enzymes may be indispensible to 
generate, at a given rate of protein biosynthesis, 
such a structurally and functionally differentiated 
pericellular connective tissue. Their identification 
would allow additional insight into the physiology 
and pathophysiology of collagen and elastin 
biosynthesis and contribute to present efforts 
towards a molecular pharmacology of the ex- 
tracellular matrix. 
Recently, substances were described that affect 
the activity either of prolyl 4-hydroxylase or of 
lysyl oxidase. The structural homology displayed 
by these compounds deserves attention. 
Designed and predicted to interfere with the 
decarboxylation phase of the catalytic ycle of pro- 
lyl 4-hydroxylase asformulated by Hanauske-Abel 
and Gtinzler, HAG [16,32], compounds like 
3,4-dihydroxyphenylacetate (3,4-DHPA) and 
pyridine-2,4-dicarboxylate (2,4-PDCA), represen- 
tative structures for class IV and class V inhibitors 
of the HAG mechanism [16], were immediately 
found to be the enzyme's most potent reversible in- 
hibitors presently available [17-19]. 2,4-PDCA is 
competitive with respect to 2-oxoglutarate [17] and 
3,4-DHPA competitive with respect to 
2-oxoglutarate and ascorbate [19], the two co- 
substrates of prolyl 4-hydroxylase [12,20]. 
2,4-PDCA was demonstrated to select for the 
2-oxoglutarate-binding site of only the collagen 
hydroxylases [18] and to inhibit specifically the 
biosynthesis of hydroxyproline-dependent pro-
teins, i.e. of fibrillar collagens and of Clq [21,32]. 
According to the pharmacokinetic model of pro- 
caine/procainamide, Hanauske-Abel designed 
organ-targeted lipophilic bioactivatable pro- 
inhibitors of 2,4-PDCA that, in carbon 
tetrachloride-induced liver fibrosis, were found to 
preserve strikingly organ function by virtue of the 
specific action [46]. 
Identified as a natural compound which is the 
cofactor of oxidoreductases in methylotropic 
bacteria [22,23], pyrroloquinoline quinone (PQQ) 
was suggested [13,24] and subsequently found 
[25,26] to be the covalently bound prosthetic group 
of lysyl oxidase. The ortho quinone arrangement 
at PQQ's C4-C5 was demonstrated to participate 
directly in the function of serum amine oxidase, 
the first quinoprotein identified in mammals 
[27,28,44,461. 
We argue that the structural homology between 
the experimental inhibitors of prolyl 4-hydroxylase 
and the natural cofactor of lysyl oxidase (figs 1,2) 
should not be dismissed as sheer coincidence, but 
should encourage attempts to investigate their 
potential role as physiological or pharmacological 
modulators of matrix formation. 
2. HYPOTHESIS 
Formation of hydroxyprolyl, i.e. conversion of 
primary structure defined proline to trans 
4-hydroxyproline residues, and formation of func- 
tional lysyl oxidase, i.e. covalent attachment of 
PQQ to lysyl oxidase apoenzyme, occur within the 
subcellular compartments that constitute the 
unidirectional route for secretory traffic of de 
novo synthesized macromolecules, i.e. the cister- 
nae of the rough endoplasmic reticulum and the 
Golgi complex. Prolyl 4-hydroxylase and the lysyl 
oxidase-specific PQQ ligase are not differentially 
accessible for the low-Mr compounds subsequently 
specified. 
PQQ reversibly inhibits prolyl 4-hydroxylase. 
The mode of inhibition is competitive with respect 
to at least one of its co-substrates. The C9 carboxyl 
function and the C4-C5 ortho quinone moiety are 
the structural prerequisites for attachment a the 
co-substrate-binding siteof the enzyme. The com- 
pound interferes with cellular peptidyl hydrox- 
yproline formation as an ascorbate antagonist and 
favors cross-link-stabilized matrix accumulation. 
Molecules that mimick PQQ's planar structure 
and the arrangement of its carboxyl groups rever- 
sibly inhibit the lysyl oxidase-specific PQQ ligase, 
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Fig.1. Structural homology between the covalently 
bound prosthetic group of lysyl oxidase, PQQ (I), and 
the prolyl 4-hydroxylase inhibitors that act either as 
specific co-substrate antagonists, i.e. pyridine-2,4-di- 
carboxylate (II) and 3,4-dihydroxyphenylacetate (III), or 
as non-specific iron chelators, like pyridine-2,6-dicar- 
boxylate (IV). As probes of the enzyme's mechanism, II 
and III were designed to interfere with the catalytic ycle 
of prolyl 4-hydroxylase [16,32] and subsequently de- 
monstrated to be the most efficient inhibitors available 
[t7-19]. The two potential interactions of PQQ with 
iron atoms are indicated by the encircled 'A' and 'B'. 
'A' designates the bidentate mode of coordination to the 
catalytic site Fe 2+ of prolyl 4-hydroxylase that is 
indispensible for effective and specific inhibition; 'B' 
designates the terdentate mode of coordination that is 
not possible at this enzyme's co-substrate-binding site
and that can occur only in solution, resulting in non- 
specific inhibition [17-19,43]. PQQ displays II, llI and 
IV as substructures. 
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Fig.2. Homology of charge distribution between the 
reduced form of PQQ, PQQH2 (1) on the one hand and 
pyridine-2,4-dicarboxylate (II) and 3,4-dihydroxyphe- 
nylacetate (III) on the other. The II-like and IIl-like 
substructures of I are electronically identical with I! and 
III, respectively. Atomic charges were calculated by the 
method of Gasteiger and Marsili [42]. 
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in this way interfering with the de novo biosyn- 
thesis of functional lysyl oxidase. 2,4-PDCA is the 
pilot structure for such PQQ ligase inhibitors. This 
compound suppresses peptidyl hydroxyproline for- 
mation as a 2-oxoglutarate antagonist and, by in- 
terfering with lysyl oxidase biosynthesis as a PQQ 
antagonist, reduces cross-link-stabilized matrix ac- 
cumulation. In this way, two crucial events in the 
matrix, deposition of both elastin and collagen, are 
rendered inefficient (elastofibrosuppressive ef-
fect). 
Molecules that mimick PQQ's C9 carbox- 
yl/C4-C5 ortho quinone substructure versibly in- 
hibit prolyl 4-hydroxylase, competitive to at least 
one of its co-substrates. The catecholamine- 
derived compounds 3,4-dihydroxymandelate nd 
3,4-dihydroxyphenylacetate are the pilot structures 
for such prolyl 4-hydroxylase inhibitors. These 
compounds inhibit peptidyl hydroxyproline for- 
mation as ascorbate antagonists (fibrosuppressive 
effect), but do not affect the lysyl oxidase-specific 
PQQ ligase and consequently cross-link stabilized 
matrix accumulation. In vivo, both substances can 
function as physiological modulators of matrix 
formation, favoring the cross-link-stabilized 
matrix accumulation of elastin and retarding that 
of collagen. 
3. DISCUSSION 
The assumption that the formation of hydrox- 
yprolyl and functional lysyl oxidase is located 
along the secretory pathway of macromolecule 
biosynthesis does not contradict any available ex- 
perimental evidence. Prolyl 4-hydroxylase occurs 
within the cisternae of the rough-surfaced en- 
doplasmic reticulum (RER) and thus is co- 
distributed with its collagen and elastin substrates, 
proteins synthesized for export [8]. Lysyl oxidase, 
active only in the extracellular space, is a secretory 
enzyme and as such will also be subject o vectorial 
transport [29], obviously as a high-Mr precursor 
[13]. There is, however, a lack of detailed informa- 
tion on the biosynthetic route of lysyl oxidase [13]. 
The finding that covalently bound PQQ con- 
stitutes its prosthetic group [25,26] implies the ex- 
istence of a specific transporter that serves to 
import the trianionic PQQ into the cisternae of the 
RER/Golgi system and of an intracisternal 
transferase that catalyses PQQ attachment to lysyl 
oxidase apoenzyme. The absence of a spon- 
taneously reactive moiety in PQQ and its occur- 
rence in just a few proteins [25,26,30,31,46] argue 
against a non-discriminating non-enzymatic at- 
tachment and justify the assumption of a PQQ 
ligase. 
PQQ, in its oxidized (fig.l) or reduced (fig.2) 
form, displays an essential structural and elec- 
tronic homology with the representative, com- 
pounds for the two classes of competitive collagen 
hydroxylase inhibitors, 3,4-DHPA and 2,4- 
PDCA. This homology identifies the atom ar- 
rangement anticipated to mediate attachment to 
the co-substrate-binding site of prolyl 4-hydroxy- 
lase. According to the HAG mechanism, 2-oxo- 
glutarate antagonists display two functional 
domains [16,32]: subsite I for electrostatic interac- 
tion with a positively charged side chain at the ac- 
tive site; and subsite II for bidentate ligation to the 
catalytic center's dZsp 3 hybridized Fe 2÷ that is 
coordinated, in cis arrangement, via three apo- 
enzyme residues. The specific co-substrate antago- 
nists 3,4-DHPA and 2,4-PDCA show these func- 
tional domains, while pyridine-2,6-dicarboxylate 
(2,6-PDCA), which only acts as a terdentate 
chelator [17,43], does not (fig.l). That is why the 
2,6-PDCA-like substructure of PQQ cannot con- 
tribute to specific prolyl 4-hydroxylase inhibition; 
this effect is predicted to result from PQQ's 3,4- 
DHPA-Iike substructure (cf. fig.l, I and III). As 
the co-substrate-binding pocket is able to accom- 
modate inhibitors as large as doxorubicin [33], the 
overall size of PQQ should not hamper its attach- 
ment. Previously, 3,4-DHPA and its analogue 
3,4-dihydroxymandelate (3,4-DHMA) were found 
to inhibit competitively prolyl 4-hydroxylase with 
respect to its two co-substrates. While their Kj 
values and the Km for 2-oxoglutarate are in the 
same range - about 10/zM - these values differ 
significantly with respect to ascorbate: the Ki 
values are at 10/zM, while the Km for ascorbate is
360/~M [19]. Obviously, 3,4-DHPA and 
3,4-DHMA are potent ascorbate antagonists in the 
prolyl 4-hydroxylase assay. In the same experimen- 
tal setting, it is reasonable to expect hat, due to its 
3,4-DHPA-Iike substructure, PQQ preferentially 
will act as an ascorbate antagonist. An easily de- 
tectable ascorbate agonist function of reduced 
PQQ is unlikely, due to at least the instability of 
PQQH2 in aqueous oxygenated media above pH 4 
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[34]; in addition, none of the ortho-dihydroxy- 
phenyl derivatives competitive with respect to 
ascorbate was able to function as a reductant for 
the purified enzyme in vitro [19]. 
It has been suggested that PQQ is the organic 
cofactor of all Cu-dependent Oz-linked amine ox- 
idases [46]. In these enzymes, its 2,6-PDCA-Iike 
substructure is anticipated to contribute to the 
active-site chelation of the transition metal [47] 
that is indispensible for any catalytic utilization of 
molecular oxygen [48]. 
Release of PQQ has been demonstrated after ex- 
tensive proteolytic treatment of lysyl oxidase [25], 
indicating that at least one of its three carboxyl 
moieties is bound via an enzymatically 
hydrolysable bond to an appropriate side chain of 
lysyl oxidase. This finding supports the prediction 
that the specific ligase requires a distinct arrange- 
ment of carboxyl groups around a planar molecule 
for attachment at its PQQ binding site. 2,4-PDCA 
fulfills this deduced structural prerequisite but 
3,4-DHPA does not: it lacks planarity and distinct- 
ly arranged carboxyls. For this reason, 0nly 
2,4-PDCA is expected to affect both crucial events 
in connective tissue formation: designed as a 
specific inhibitor of prolyl 4-hydroxylase and 
therefore collagenous protein secretion [16,32], it 
is also predicted to be an inhibitor of the 
postulated PQQ ligase, interfering with the biosyn- 
thesis of functional lysyl oxidase and therefore 
with cross-link-stabilized matrix accumulation. In 
either case, the mode of action of 2,4-PDCA is 
reversible and competitive to each enzyme's co- 
substrate, i.e. 2-oxoglutarate or PQQ. 
In contrast o 2,4-PDCA, which is not a known 
product of mammalian intermediary metabolism, 
both 3,4-DHPA and 3,4-DHMA are physiological- 
ly occurring compounds generated in the catabolic 
pathways of dopamine [35] and of nor- 
epinephrine/epinephrine [36], respectively. 
Humans synthesize the catecholamine metabolites 
3,4-DHPA and 3,4-DHMA in milligram amounts 
per day [36,37]. The catecholamines are known to 
exert vital effects in the cardiovascular system [38], 
the same system that has elastin as a dominant 
structural protein [39]. The finding that 
3,4-DHPA and 3,4-DHMA are potent ascorbate 
antagonists for prolyl 4-hydroxylase [19] and the 
reports on enhanced cross-link-stabilized elastin 
accumulation i the matrix of ascorbate-deprived, 
i.e. prolyl 4-hydroxylase-suppressed cell cultures 
[5-7], suggest that 3,4-DHPA and 3,4-DHMA 
may not be biologically inert degradation prod- 
ucts: both have the potential to produce 
physiologically a relative ascorbate deficiency ex- 
clusively within the cisternae of the RER of suscep- 
tible cells, thus damping fibrogenesis via reduced 
secretion of hydroxyproline-rich triple-helical col- 
lagen, while boosting elastogenesis via secretion of 
hydroxyproline-deficient coacervate-prone elastin. 
In this way, the catecholamine metabolites 
3,4-DHPA and 3,4-DHMA could biochemically 
contribute to the functionally required structure of 
vessels which bear the brunt of the catecholamine's 
biophysical effects. At least the generation of 
3,4-DHPA from dopamine is in part dependent on 
a quinoprotein [44]. 
Considering the structure-activity relationship 
predicted and later verified for prolyl 
4-hydroxylase antagonists [16-19,32] and the 
structure-activity relationship predicted here for 
the PQQ ligase, formulas for compounds can be 
suggested that may act as catalytic inbibitors of 
prolyl 4-hydroxylase and as biosynthetic nhibitors 
of lysyl oxidase. As shown in fig.3, omission of the 
ortho quinone moiety of PQQ and bioisosteric ex- 
change of -NH- for -CHz- gives structure I whose 
arrangement of carboxyl groups is unaffected. 
Although prolyl 4-hydroxylase is inhibited by 
pyridine-2,5-dicarboxylate [17], indicating that the 
presence of a carboxyl function at the pyridine's 
C5 is well tolerated; the rigid bulky ring at C5 of 
structure I may interfere with effective attachment 
at the co-substrate-binding site. In structure II 
(fig.3) it was therefore substituted with a flexible 
aliphatic residue; its length may antagonistically 
affect the inhibitor's efficiency towards the 
hydroxylase and the ligase. As the subcellular 
target site - the cisternae of the RER/Golgi system 
- is shielded by two lipid barriers, the cytoplasmic 
and compartmental membranes, access of 
hydrophilic ompounds like I and II is effectively 
blocked in vivo. Lipophilic bioactivatable pro- 
inhibitors, however, can be expected to reduce 
essentially the concentrations required for suppres- 
sion of the intracisternal enzymes. In tissue culture 
and in the experimental nimal, this approach was 
successfully used for 2,4-PDCA-mediated 
fibrosuppression [40,45]. The strategy holds the 
potential of restricting the intended effect to cer- 
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Fig.3. Design of structures potentially inhibitory both for prolyl 4-hydroxylase and for PQQ ligase. 
tain organs as well, as an effective pro- 
inhibitor-inhibitor conversion has to occur in- 
tracellularly, and the pro-inhibitor activation can 
be designed to depend upon the metabolic 
peculiarities of the tissue at which the inhibitor's 
activity is aimed. Structure III of fig.3 exclusively 
serves to exemplify the theoretical combination of 
two different modifications reversibly masking the 
inhibitor's crucial carboxyl arrangement: amide 
and acetal formation. Biotransformation f an un- 
polar inactive pro-inhibitor like III, or its 
triethylamide analogue, to the polar active in- 
hibitor is anticipated to occur preferentially in the 
portal system [41], regionally suppressing both 
peptidyl hydroxyproline formation and cross- 
linked-stabilized matrix accumulation - two highly 
desirable ffects in any preventive or curative treat- 
ment of fibrotic liver diseases. In contrast, scarring 
processes compromising the function of elastic 
tissues, e.g. lung fibrosis, may respond to selective 
inhibition of hydroxyprolyl formation by 
3,4-DHPA-derived pro-inhibitors that should not 
compromise lastogenesis. 
For compounds of both the 2,4-PDCA and 
3,4-DHPA class, pro-inhibitor targeting by 
specific chemical modifications and selective 
routes of administration to modulate connective 
tissue formation locally can be conceptualized that 
will prevent detrimental matrix alterations in 
distinct organs which otherwise disrupt their 
physiological function. 
The demonstration that the reversible prolyl 
4-hydroxylase inhibitors and the prosthetic group 
of lysyl oxidase share unique structural features is 
indicative of a common modulating mechanism 
that, at a given rate of protein biosynthesis, links 
post-translational events occurring 'upstream' and 
'downstream' in extracellular matrix biosynthesis. 
The homology between 3,4-DHPA/3,4-DHMA/ 
2,4-PDCA and PQQ holds biochemical implica- 
tions relevant o the physiology and pathology of 
connective tissue formation and suggests that 
fibrogenesis and elastogenesis are differentially 
amenable to pharmacological therapeutics. 
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